LEXINGTON, Mass., June 30, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO) , a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced results from its ongoing data analysis of the first cohort of its Phase 2, sequential multiple dose study evaluating the safety and efficacy of ErepoXen ® , subcutaneously administered polysialylated erythropoietin (PSA-EPO), for the treatment of anemia in Chronic Kidney Disease (CKD) patients who are neither on dialysis nor receiving erythropoiesis stimulating agents.
RICHMOND, Va., July 1, 2014 (GLOBE NEWSWIRE) -- Xenith Bankshares, Inc. (Nasdaq:XBKS) , parent company of Xenith Bank, today announced the completion of its acquisition of Colonial Virginia Bank ("CVB"), whereby CVB was merged with and into Xenith Bank.
XenoPort, Inc. (Nasdaq:XNPT) and the National Institute on Alcohol Abuse
and Alcoholism (NIAAA) announced today that they have entered into an
agreement to conduct a clinical trial of HORIZANT ®
(gabapentin enacarbil) Extended-Release Tablets as a potential treatment
for alcohol use disorder (AUD). Under the terms of the agreement,
XenoPort will supply clinical trial material and the NIAAA will conduct
and pay all other expenses associated with the proposed clinical trial
YOUNGSVILLE, N.C., July 31, 2014 (GLOBE NEWSWIRE) -- Xerium Technologies, Inc. (NYSE:XRM) , a leading global provider of industrial consumable products and services, today announced that it has initiated closure proceedings with the representative union officials at its PMC facility in João Pessoa, Brazil.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.